Zachary Roberts's Insider Trades & SAST Disclosures
Zachary Roberts's most recent trade in Allogene Therapeutics Inc was a trade of 18,832 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Feb. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Zachary Roberts.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | Zachary Roberts | EVP of R&D | Sale of securities on an exchange or to another person at price $ 1.70 per share. | 03 Feb 2025 | 18,832 | 643,135 (0%) | 0% | 1.7 | 32,014 | Common Stock |
| Allogene Therapeutics Inc | Zachary Roberts | EVP of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 614,844 | 614,844 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Zachary Roberts | EVP of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 173,913 | 661,967 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Zachary Roberts | EVP of R&D | Sale of securities on an exchange or to another person at price $ 1.78 per share. | 21 Jan 2025 | 27,199 | 488,054 (0%) | 0% | 1.8 | 48,414 | Common Stock |
| Allogene Therapeutics Inc | Roberts Zachary | EVP of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 494,949 | 494,949 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Roberts Zachary | EVP of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 140,000 | 515,253 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Roberts Zachary | EVP of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 22 Jan 2024 | 24,690 | 375,253 (0%) | 0% | 3.2 | 78,376 | Common Stock |
| Allogene Therapeutics Inc | Zachary Roberts | EVP of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 148,035 | 399,943 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Zachary Roberts | EVP of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 873,015 | 873,015 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Zachary Roberts | EVP of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 251,908 | 251,908 (0%) | 0% | 0 | Common Stock | |
| Instil Bio Inc | Zachary Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 245,000 | 245,000 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Zachary Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 120,000 | 240,000 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Zachary Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2021 | 120,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Zachary Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Instil Bio Inc | Zachary Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 240,000 | 240,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges